STTK 1.40 Shattuck Labs, Inc.
| Range: | 1.07-11.76 | Vol Avg: | 557128 | Last Div: | 0 | Changes: | -0.03 |
| Beta: | 1.73 | Cap: | 0.06B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Oct 09 2020 | Empoloyees: | 75 | ||
| CUSIP: | 82024L103 | CIK: | 0001680367 | ISIN: | US82024L1035 | Country: | US |
| CEO: | Dr. Taylor H. Schreiber M.D., Ph.D. | Website: | https://www.shattucklabs.com | ||||
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Stock Details
STTK 8
Shattuck Labs price target lowered to $8 from $9 at Citi
Yigal Nochomovitz·Thu Aug 15 2024
Citigroup
STTK 16
Shattuck Labs (STTK) PT Lowered to $16 at H.C. Wainwright
Joseph Pantginis·Thu Jun 20 2024
H.C. Wainwright
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow